- Home
- AIG vs ILMN Comparison
AIG vs ILMN Comparison
Compare AIG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIG | ILMN |
|---|---|---|
| Founded | 1919 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8B | 37.0B |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIG | ILMN |
|---|---|---|
| Price | $74.66 | $269.73 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 17 |
| Target Price | $86.46 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 3.7M | 2.3M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 350.23 | 170.87 |
| EPS | ★ 3.18 | 2.22 |
| Revenue | ★ $26,775,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $11.55 | $6.47 |
| Revenue Next Year | $5.26 | $5.58 |
| P/E Ratio | ★ $22.89 | $122.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.25 | $88.00 |
| 52 Week High | $87.35 | $277.95 |
Technical Indicators
Market Signals| Indicator | AIG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 71.84 |
| Support Level | $73.06 | $116.43 |
| Resistance Level | $78.13 | N/A |
| Average True Range (ATR) | 1.41 | 12.34 |
| MACD | -0.12 | 4.29 |
| Stochastic Oscillator | 46.85 | 86.38 |
Price Performance
Historical ComparisonAbout AIG American International Group Inc. New
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.